Keith L Knutson

List of Publications by Year
in descending order

91	13,352	57758 44	45317 90
papers	citations	h-index	g-index

93	93	93	16972
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine, 2004, 10, 942-949.	30.7	4,442
2	Blockade of B7-H1 improves myeloid dendritic cellâ€“mediated antitumor immunity. Nature Medicine, 2003, 9, 562-567.	30.7	1,157
3	Next generation of immune checkpoint therapy in cancer: new developments and challenges. Journal of Hematology and Oncology, 2018, 11, 39.	17.0	597
4	Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptideâ€“Based Vaccines. Journal of Clinical Oncology, 2002, 20, 2624-2632.	1.6	411
5	Immune-Induced Epithelial to Mesenchymal Transition In vivo Generates Breast Cancer Stem Cells. Cancer Research, 2009, 69, 2887-2895.	0.9	369
6	Tumor-Infiltrating Dendritic Cells in Cancer Pathogenesis. Journal of Immunology, 2015, 194, 2985-2991.	0.8	369
7	Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. Journal of Clinical Investigation, 2001, 107, 477-484.	8.2	368
8	Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecologic Oncology, 2008, 108, 619-626.	1.4	365
9	The Microbiome of Aseptically Collected Human Breast Tissue in Benign and Malignant Disease. Scientific Reports, 2016, 6, 30751.	3.3	299
10	Intraepithelial Effector (CD3+)/Regulatory (FoxP3+) T-Cell Ratio Predicts a Clinical Outcome of Human Colon Carcinoma. Gastroenterology, 2009, 137, 1270-1279.	1.3	273
11	Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clinical Cancer Research, 2002, 8, 1014-8.	7.0	210
12	Tumor-Infiltrating Programmed Death Receptor-1+ Dendritic Cells Mediate Immune Suppression in Ovarian Cancer. Journal of Immunology, 2011, 186, 6905-6913.	0.8	209
13	Augmented HER-2â€“Specific Immunity during Treatment with Trastuzumab and Chemotherapy. Clinical Cancer Research, 2007, 13, 5133-5143.	7.0	194
14	Tumor-Infiltrating Foxp3â^'CD4+CD25+ T Cells Predict Poor Survival in Renal Cell Carcinoma. Clinical Cancer Research, 2007, 13, 2075-2081.	7.0	188
15	Cancer immunotherapy beyond immune checkpoint inhibitors. Journal of Hematology and Oncology, 2018, 11, 8.	17.0	174
16	The Ratios of CD8+ T Cells to CD4+CD25+ FOXP3+ and FOXP3- T Cells Correlate with Poor Clinical Outcome in Human Serous Ovarian Cancer. PLoS ONE, 2013, 8, e80063.	2.5	171
17	Tumor immunoediting and immunosculpting pathways to cancer progression. Seminars in Cancer Biology, 2007, 17, 275-287.	9.6	167
18	Oncolytic Measles Virus Expressing the Sodium Iodide Symporter to Treat Drug-Resistant Ovarian Cancer. Cancer Research, 2015, 75, 22-30.	0.9	157

#	Article	IF	Citations
19	Effect of Dose on Immune Response in Patients Vaccinated With an HER-2/neu Intracellular Domain Proteinâ€"Based Vaccine. Journal of Clinical Oncology, 2004, 22, 1916-1925.	1.6	149
20	Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Research and Treatment, 2000, 62, 245-252.	2.5	139
21	Accumulation of Memory Precursor CD8 T Cells in Regressing Tumors following Combination Therapy with Vaccine and Anti-PD-1 Antibody. Cancer Research, 2014, 74, 2974-2985.	0.9	136
22	Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy. Nature Nanotechnology, 2017, 12, 763-769.	31.5	136
23	IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer. Cancer Research, 2017, 77, 6667-6678.	0.9	126
24	IL-2 Immunotoxin Therapy Modulates Tumor-Associated Regulatory T Cells and Leads to Lasting Immune-Mediated Rejection of Breast Cancers in neu-Transgenic Mice. Journal of Immunology, 2006, 177, 84-91.	0.8	118
25	Immunoediting of Cancers May Lead to Epithelial to Mesenchymal Transition. Journal of Immunology, 2006, 177, 1526-1533.	0.8	116
26	Humoral Epitope-Spreading Following Immunization with a HER-2/neu Peptide Based Vaccine in Cancer Patients. Journal of Clinical Immunology, 2004, 24, 571-578.	3.8	104
27	Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. Journal of Translational Medicine, 2010, 8, 53.	4.4	104
28	Immunity and immune suppression in human ovarian cancer. Immunotherapy, 2011, 3, 539-556.	2.0	102
29	CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunology, Immunotherapy, 2006, 56, 271-285.	4.2	100
30	Immune Promotion of Epithelial-mesenchymal Transition and Generation of Breast Cancer Stem Cells. Cancer Research, 2010, 70, 3005-3008.	0.9	99
31	Peptide Vaccine Given with a Toll-Like Receptor Agonist Is Effective for the Treatment and Prevention of Spontaneous Breast Tumors. Cancer Research, 2007, 67, 1326-1334.	0.9	97
32	HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. European Journal of Immunology, 2007, 37, 675-685.	2.9	92
33	PD-1 Blunts the Function of Ovarian Tumorâ€"Infiltrating Dendritic Cells by Inactivating NF-ÎºB. Cancer Research, 2016, 76, 239-250.	0.9	84
34	The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity. Blood, 2008, 111, 1472-1479.	1.4	71
35	T-Cell Immunity to the Folate Receptor Alpha Is Prevalent in Women With Breast or Ovarian Cancer. Journal of Clinical Oncology, 2006, 24, 4254-4261.	1.6	68
36	Functional Folate Receptor Alpha Is Elevated in the Blood of Ovarian Cancer Patients. PLoS ONE, 2009, 4, e6292.	2.5	64

#	Article	IF	Citations
37	Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clinical Cancer Research, 2018, 24, 3014-3025.	7.0	64
38	neu Antigen-Negative Variants Can Be Generated after neu-Specific Antibody Therapy in neu Transgenic Mice. Cancer Research, 2004, 64, 1146-1151.	0.9	63
39	Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clinical Cancer Research, 2003, 9, 5559-65.	7.0	62
40	The Immune System in the Pathogenesis of Ovarian Cancer. Critical Reviews in Immunology, 2013, 33, 137-164.	0.5	55
41	Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer. Cancer Immunology, Immunotherapy, 2015, 64, 1495-1504.	4.2	51
42	Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain. Cancer Research, 2016, 76, 3702-3710.	0.9	51
43	The Tumor Antigen Repertoire Identified in Tumor-Bearing Neu Transgenic Mice Predicts Human Tumor Antigens. Cancer Research, 2006, 66, 9754-9761.	0.9	50
44	Macrophagic â€œCrown-like Structuresâ€•Are Associated with an Increased Risk of Breast Cancer in Benign Breast Disease. Cancer Prevention Research, 2018, 11, 113-119.	1.5	50
45	Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients. Npj Breast Cancer, 2020, 6, 4.	5.2	49
46	Alterations in the Immune Cell Composition in Premalignant Breast Tissue that Precede Breast Cancer Development. Clinical Cancer Research, 2017, 23, 3945-3952.	7.0	46
47	Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients. Nature Communications, 2020, 11, 5173.	12.8	46
48	Association Studies of Fcî³ Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831. Cancer Immunology Research, 2014, 2, 962-969.	3.4	44
49	Downregulation of TAP1 and TAP2 in early stage breast cancer. PLoS ONE, 2017, 12, e0187323.	2.5	38
50	Tumor Antigenâ€“Specific T-Cell Expansion Is Greatly Facilitated by In vivo Priming. Clinical Cancer Research, 2007, 13, 1883-1891.	7.0	34
51	Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial. , 2020, 8, e000829.		34
52	Tumor Hypomethylation at 6p21.3 Associates with Longer Time to Recurrence of High-Grade Serous Epithelial Ovarian Cancer. Cancer Research, 2014, 74, 3084-3091.	0.9	32
53	Plasma immune analytes in patients with epithelial ovarian cancer. Cytokine, 2015, 73, 108-113.	3.2	31
54	Expansion of HER2/neu-Specific T Cells Ex Vivo Following Immunization with a HER2/neu Peptide-Based Vaccine. Clinical Breast Cancer, 2001, 2, 73-79.	2.4	28

#	Article	IF	Citations
55	Adoptive T cell therapy of solid cancers. Cancer Immunology, Immunotherapy, 2006, 55, 96-103.	4.2	28
56	Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses. Blood Advances, 2020, 4, 2143-2157.	5.2	27
57	HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer. OncoImmunology, 2020, 9, 1744947.	4.6	26
58	Soluble Cytokines Can Act as Effective Adjuvants in Plasmid DNA Vaccines Targeting Self Tumor Antigens. Immunobiology, 2003, 207, 179-186.	1.9	24
59	Immune checkpoint inhibition by antiâ€‹<scp>PDCD</scp>1 (antiâ€‹<scp>PD</scp>1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model. British Journal of Haematology, 2018, 183, 674-678.	2.5	22
60	Laboratory Analysis of T-Cell Immunity. Frontiers in Bioscience - Landmark, 2006, 11, 1932.	3.0	21
61	Large-Scale Evaluation of Common Variation in Regulatory T Cellâ€“Related Genes and Ovarian Cancer Outcome. Cancer Immunology Research, 2014, 2, 332-340.	3.4	21
62	Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce â€œdanger signalsâ€. Breast Cancer Research and Treatment, 2006, 96, 233-241.	2.5	20
63	Inherited Variants in Regulatory T Cell Genes and Outcome of Ovarian Cancer. PLoS ONE, 2013, 8, e53903.	2.5	20
64	Immunotherapeutic approaches for the treatment of breast cancer. Journal of Mammary Gland Biology and Neoplasia, 1999, 4, 353-365.	2.7	19
65	Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient. Human Immunology, 2002, 63, 547-557.	2.4	18
66	Cytokine and neuropeptide levels are associated with pain relief in patients with chronically painful total knee arthroplasty: a pilot study. BMC Musculoskeletal Disorders, 2017, 18, 17.	1.9	18
67	Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapy. Immunotherapy, 2019, 11, 577-584.	2.0	18
68	Adoptive T-cell therapy for the treatment of solid tumours. Expert Opinion on Biological Therapy, 2002, 2, 55-66.	3.1	16
69	An HLA-DRâ€“Degenerate Epitope Pool Detects Insulin-like Growth Factor Binding Protein 2â€“Specific Immunity in Patients with Cancer. Cancer Research, 2008, 68, 4893-4901.	0.9	16
70	A Degenerate HLA-DR Epitope Pool of HER-2/neu Reveals a Novel In vivo Immunodominant Epitope, HER-2/neu88-102. Clinical Cancer Research, 2010, 16, 825-834.	7.0	15
71	MHC Class II Epitope Nesting Modulates Dendritic Cell Function and Improves Generation of Antigen-Specific CD4 Helper T Cells. Journal of Immunology, 2011, 187, 316-324.	0.8	15
72	Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine. Clinical Cancer Research, 2020, 26, 1045-1053.	7.0	13

#	Article	IF	Citations
73	Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen. Cancer Immunology, Immunotherapy, 2010, 59, 161-171.	4.2	12
74	Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer. Breast Cancer Research, 2018, 20, 52.	5.0	12
75	Immune Responses and Risk of Triple-negative Breast Cancer: Implications for Higher Rates among African American Women. Cancer Prevention Research, 2020, 13, 901-910.	1.5	10
76	Humoral Responses After SARS-CoV-2 mRNA Vaccination and Breakthrough Infection in Cancer Patients. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2022, 6, 120-125.	2.4	10
77	The Association of Peripheral Blood Regulatory T-Cell Concentrations With Epithelial Ovarian Cancer: A Brief Report. International Journal of Gynecological Cancer, 2017, 27, 11-16.	2.5	9
78	Therapeutic vaccines for malignant brain tumors. Biologics: Targets and Therapy, 2008, 2, 753.	3.2	8
79	Cancer vaccines in the new era of cancer immunotherapy. Vaccine, 2015, 33, 7376.	3.8	7
80	Strong-arming immune regulation: suppressing regulatory T-cell function to treat cancers. Future Oncology, 2006, 2, 379-389.	2.4	6
81	Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials. Clinical Cancer Research, 2019, 25, 4422-4430.	7.0	6
82	Longitudinal relationships between rheumatoid factor and cytokine expression by immunostimulated peripheral blood lymphocytes from patients with rheumatoid arthritis: New insights into B-cell activation. Clinical Immunology, 2020, 211, 108342.	3.2	6
83	Dynamic control of tumor vasculature improves antitumor responses in a regional model of melanoma. Scientific Reports, 2020, 10, 13245.	3.3	6
84	A pilot trial of intravital microscopy in the study of the tumor vasculature of patients with peritoneal carcinomatosis. Scientific Reports, 2021, 11, 4946.	3.3	5
85	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 2016, 7, 69097-69110.	1.8	5
86	Cytotoxic T cell depletion with increasing epithelial abnormality in women with benign breast disease. Breast Cancer Research and Treatment, 2020, 180, 55-61.	2.5	4
87	Immunotherapy for breast cancer. Cancer Chemotherapy and Biological Response Modifiers, 2002, 20, 351-69.	0.5	4
88	Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials. Npj Breast Cancer, 2022, 8, .	5.2	4
89	Cancer vaccines: The next generation. Drug Discovery Today: Therapeutic Strategies, 2005, 2, 323-330.	0.5	2
90	Antibodies in cancer immunotherapy. Cancer Biomarkers, 2010, 6, 291-305.	1.7	2

#	Article	IF	Citations
91	The Immune System in Breast Cancer Initiation and Progression: Role of Epithelial to Mesenchymal Transition. , 2013, , 43-64.		0